Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: A pre-/post-study

Internal Medicine Journal

Volumn 42, Issue 4, 2012, Pages

  Manotham, K ^a   Ongvilawan, B ^a,b   Urusopone, P ^a   Chetsurakarn, S ^a   Tanamai, J ^a   Limkuansuwan, P ^a   Tungsanga, K ^c   Eiam Ong, S ^c  

^a LERDSIN GENERAL HOSPITAL   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Angiotensin II receptor blocker; Blood oxygen level dependent magnetic resonance imaging; Chronic kidney disease; Hypoxia; Kidney failure

Indexed keywords

OLMESARTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BOLD SIGNAL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; HYPOXIA; INTRARENAL HYPOXIA; KIDNEY DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TISSUE OXYGENATION;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANOXIA; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXYGEN; RENAL INSUFFICIENCY, CHRONIC; TETRAZOLES; YOUNG ADULT;

EID: 84859856686     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02610.x     Document Type: Article

References (24)

1. Dirks JH, de Zeeuw D, Agarwal SJ, Atkins RC, Correa-Rotter R, D'Amico G etal. Prevention of chronic kidney and vascular disease: toward global health equity - the Bellagio 2004 declaration. Kidney Int Suppl 2005; (98): S1-S6.
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB etal. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH etal. Effects of losartan on renal and cardiovascular out come in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-78.
5. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8.
6. Miyata T, de Strihou C. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006; 21: 846-9.
7. Manotham K, Tanaka T, Matsumoto M etal. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15: 1277-88.
8. Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M. Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 2004; 165: 1979-92.
9. Matsumoto M, Tanaka T, Yamamoto T, Noiri E, Miyata T, Inagi R etal. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 2004; 15: 1574-81.
10. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal disease other than proteinuria? towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000; 75: S22-S26.
11. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS etal. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 2005; (99): S46-S51.
12. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal disease. J Am Soc Nephrol 2006; 17: 17-25.
13. 2 indicating a novel potential renoprotective action. Nephron Physiol 2003; 94: 39-46.
14. Prasad PV, Edelman RR, Epstein FH. Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circulation 1996; 94: 3271-5.
15. Tumkur SM, Vu AT, Li LP, Pierchala L, Prasad PV. Evaluation of intra-renal oxygenation during water diuresis: a time-resolved study using BOLD MRI. Kidney Int 2006; 70: 139-43.
16. Hofmann L, Simon-Zoula S, Nowak A, Giger A, Vock P, Boesch C etal. BOLD-MRI for the assessment of renal oxygenation in humans: acute effect of nephrotoxic xenobiotics. Kidney Int 2006; 70: 144-50.
17. Li LP, Storey P, Pierchala L, Li W, Polzin J, Prasad P. Evaluation of the reproducibility of intrarenal R2* and DeltaR2* measurements following administration of furosemide and during waterload. J Magn Reson Imaging 2004; 19: 610-16.
18. Schachinger H, Klarhofer M, Linder L, Drewe J, Scheffler K. Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. Hypertension 2006; 47: 1062-6.
19. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL etal. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434-47.
20. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996; 19: 191-5.
21. Welch WJ, Baumgärtl H, Lübbers D, Wilcox CS. Nephron pO2 and renal oxygen usage in the hypertensive rat kidney. Kidney Int 2001; 59: 230-37.
22. Welch WJ, Baumgärtl H, Lübbers D, Wilcox CS. Renal oxygenation defects in the spontaneously hypertensive rat: role of AT1 receptors. Kidney Int 2003; 63: 202-8.
23. Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 2008; 31: 175-84.
24. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986; 80: 435-22.